MedPath

Proenkephalin A and Kidney Replacement Therapy

Terminated
Conditions
Acute Kidney Injury
Interventions
Other: None planned
Registration Number
NCT04879706
Lead Sponsor
University of Giessen
Brief Summary

Acute kidney injury (AKI) is a common problem encountered in the intensive care unit (ICU), estimated to occur in up to 60% of all critically ill patients, depending on the definition. Recent large randomized clinical trials in critical care nephrology have focused on the optimal timing of initiation of acute kidney replacement therapy (KRT). However, less is known about the ideal circumstances in which KRT may be successfully discontinued.

The novel serum-biomarker proenkephalin A 119-159 (penkid) has been found to be strongly negatively correlated with measured GFR. Whether penkid may have a role in initiation and discontinuation of KRT remains unknown.

Detailed Description

Acute kidney injury (AKI) is a common problem encountered in the intensive care unit (ICU), estimated to occur in up to 60% of all critically ill patients, depending on the definition. Recent large randomized clinical trials in critical care nephrology have focused on the optimal timing of initiation of acute kidney replacement therapy (KRT). However, less is known about the ideal circumstances in which KRT may be successfully discontinued. KRT is a complex and expensive therapy, with complications including catheter-associated infections, hemorrhage, hemodynamic instability, and potential delayed renal recovery.

The novel serum-biomarker proenkephalin A 119-159 (penkid) is a stable fragment derived from the precursor enkephalins, which are known as small endogenous opioid peptides and are produced throughout the human body, including the kidneys. Plasma concentrations of penkid have been found to be strongly negatively correlated with measured glomerular filtration rate. Whether penkid may have a role in initiation and discontinuation of KRT remains unknown.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Patients ≥18 years of age with AKI requiring KRT
Exclusion Criteria
  • Chronic kidney disease with estimated glomerular filtration rate <30 mL/min/1.73 m2
  • Non-end stage renal disease with extracorporeal ultrafiltration due to diuretic- resistant fluid overload
  • Decision to limit therapeutic interventions
  • History of solid-organ transplants
  • Pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
AKI necessitating KRTNone plannedPatients with AKI necessitating KRT
Primary Outcome Measures
NameTimeMethod
Penkid levels at discontinuation of KRTUp to 2 weeks

Serial assessment of penkid in patients undergoing KRT

Penkid levels at KRT initiationUp to 2 weeks

Serial assessment of penkid in patients undergoing KRT

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Hospital Gießen and Marburg

🇩🇪

Gießen, Hessen, Germany

© Copyright 2025. All Rights Reserved by MedPath